The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
Abstract Introduction Little is known about the burden of hereditary transthyretin (ATTRv) amyloidosis, a genetic, progressive, and fatal disease caused by extracellular deposition of transthyretin amyloid fibrils. The study’s aim was to estimate costs and disease burden associated with ATTRv amyloi...
Main Authors: | Sheila R. Reddy, Eunice Chang, Marian H. Tarbox, Michael S. Broder, Ryan S. Tieu, Spencer Guthrie, Montserrat Vera-Llonch, Michael R. Pollock |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-05-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40120-020-00194-4 |
Similar Items
-
The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
by: Montserrat Vera-Llonch, et al.
Published: (2021-01-01) -
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
by: Hiroaki Matsushita, et al.
Published: (2022-06-01) -
Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
by: Andrew Lovley, et al.
Published: (2021-01-01) -
Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features
by: Zoltán Pozsonyi, et al.
Published: (2021-07-01) -
Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
by: Hiroki Yamaguchi, et al.
Published: (2022-03-01)